Zobrazeno 1 - 10
of 39
pro vyhledávání: '"GRAHAM P. ALLAWAY"'
Autor:
Cheryl A Stoddart, Pheroze Joshi, Barbara Sloan, Jennifer C Bare, Philip C Smith, Graham P Allaway, Carl T Wild, David E Martin
Publikováno v:
PLoS ONE, Vol 2, Iss 11, p e1251 (2007)
The HIV-1 maturation inhibitor, 3-O-(3',3'-dimethylsuccinyl) betulinic acid (bevirimat, PA-457) is a promising drug candidate with 10 nM in vitro antiviral activity against multiple wild-type (WT) and drug-resistant HIV-1 isolates. Bevirimat has a no
Externí odkaz:
https://doaj.org/article/767cee83f8bd4f77a00802dac5c2710b
Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation
Autor:
Katherine Crisafi, Abdul S. Yunus, Karl Salzwedel, Nicole Kilgore, Dorian Zoumplis, Carl T. Wild, Trent P. Jackson, Graham P. Allaway, Irina Burimski
Publikováno v:
Virology
Human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infection in infants, immunocompromised patients, and the elderly. The RSV fusion (F) protein mediates fusion of the viral envelope with the target cell membra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb7221d6eceb4d684945a736076ba61c
Publikováno v:
Antiviral Chemistry and Chemotherapy. 19:107-113
Existing antiretroviral treatments for HIV type-1 (HIV-1) disease are limited by problems of resistance and drug-drug interactions. Bevirimat is a novel HIV-1 maturation inhibitor with a mechanism of action that is distinct from other antiretroviral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b1f4dcf08b02d9866ea645ee01b4c2a
https://doi.org/10.1177/095632020801900301
https://doi.org/10.1177/095632020801900301
Autor:
Keduo Qian, Nicole Kilgore, Susan L. Morris-Natschke, Graham P. Allaway, Kuo Hsiung Lee, Donglei Yu, Kyoko Nakagawa-Goto, Theodore J. Nitz
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:6553-6557
3-O-3′(or 2′)-Methylsuccinyl-betulinic acid (MSB) derivatives were separated by using recycle HPLC. The structures of four isomers were assigned by NMR and asymmetric synthesis. 3-O-3′S-Methylsuccinyl-betulinic acid (3′S-MSB, 4) exhibited pot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c0b78eed11e0308a26167efa515c8ed
https://doi.org/10.1016/j.bmcl.2007.09.081
https://doi.org/10.1016/j.bmcl.2007.09.081
Autor:
John H. Wilton, David E. Martin, Karl Salzwedel, Alan Forrest, Patrick F. Smith, Judy Doto, Abayomi B. Ogundele, Graham P. Allaway
Publikováno v:
Antimicrobial Agents and Chemotherapy. 51:3574-3581
Bevirimat [3-O-(3,3-dimethylsuccinyl)betulinic acid] is the first in a new class of anti-human immunodeficiency virus (HIV) drugs that inhibit viral maturation by specifically blocking cleavage of the Gag capsid (CA) precursor, CA-SP1, to mature CA p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d7191356544a2063e8aea1a41a9ad9a
https://doi.org/10.1128/aac.00152-07
https://doi.org/10.1128/aac.00152-07
Autor:
Karl Salzwedel, Eric O. Freed, Dorian Zoumplis, Feng Li, Catherine S. Adamson, Abdul S. Yunus, Claudia Matallana, Nicole Kilgore, David E. Martin, Mary Reddick, Graham P. Allaway, Carl T. Wild
Publikováno v:
Virology. 356(1-2):217-224
3-O-(3′,3′-dimethylsuccinyl) betulinic acid, also termed PA-457 or DSB, is a novel HIV-1 inhibitor that blocks virus maturation by disrupting cleavage of the capsid precursor, CA-SP1. To better define the molecular target for PA-457, we prepared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cb41eb9e97f38030f6cb185d96e9599
Autor:
Chin Ho Chen, Graham P. Allaway, Carl T. Wild, Donglei Yu, Susan L. Morris-Natschke, David E. Martin, Kuo Hsiung Lee
Publikováno v:
Expert Opinion on Investigational Drugs. 14:681-693
Although HIV infection is now primarily treated with reverse transcriptase and protease inhibitors, HIV therapy must look toward new drugs with novel mechanism(s) of action to both improve efficacy and address the growing problem of drug resistance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aea79a76845cc7e93d99aa10364f6351
https://doi.org/10.1517/13543784.14.6.681
https://doi.org/10.1517/13543784.14.6.681
Autor:
Carl T. Wild, Graham P. Allaway, A. Castillo, C. Matallana, Ritu Goila-Gaur, Jan M. Orenstein, Dorian Zoumplis, Mary Reddick, David E. Martin, Karl Salzwedel, Nicole Kilgore, Eric O. Freed, Feng Li
Publikováno v:
Proceedings of the National Academy of Sciences. 100:13555-13560
New HIV therapies are urgently needed to address the growing problem of drug resistance. In this article, we characterize the anti-HIV drug candidate 3- O -(3′,3′-dimethylsuccinyl) betulinic acid (PA-457). We show that PA-457 potently inhibits re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d3619dca73452bfea25939b902ef980
https://doi.org/10.1073/pnas.2234683100
https://doi.org/10.1073/pnas.2234683100
Autor:
Paul J. Maddon, James Arthos, John P. Moore, James M. Binley, Tatjana Dragic, Cecilia Cheng-Mayer, Alexandra Trkola, James E. Robinson, Graham P. Allaway, William C. Olson
Publikováno v:
Nature. 384:184-187
The beta-chemokine receptor CCR-5 is an essential co-factor for fusion of HIV-1 strains of the non-syncytium-inducing (NSI) phenotype with CD4+ T-cells. The primary binding site for human immunodeficiency virus (HIV)-1 is the CD4 molecule, and the in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c74f99fb9683b0f6192ec17b50ff1724
https://doi.org/10.1038/384184a0
https://doi.org/10.1038/384184a0
Autor:
Richard A. Koup, Graham P. Allaway, Marie Claire Gauduin, Paul J. Maddon, Dennis R. Burton, Carlos F. Barbas
Publikováno v:
Journal of Virology. 70:2586-2592
We tested the ability of human monoclonal antibodies (immunoglobulin G1b12 [IgG1b12] and 19b) and CD4-based molecules (CD4-IgG2 and soluble CD4 [sCD4]) to neutralize human immunodeficiency virus type 1 directly from the plasma of seropositive donors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62f4e8711cad29efc9e6aaaefcd1e985
https://doi.org/10.1128/jvi.70.4.2586-2592.1996
https://doi.org/10.1128/jvi.70.4.2586-2592.1996